Faruqi & Faruqi, LLP Announces Preliminary Court Approval of Settlement in Mylan Pharmaceuticals, Inc., et al. v. Warner Chilcott Public Limited Co., et al.

Faruqi & Faruqi, LLP Announces Preliminary Court Approval of Settlement in Mylan Pharmaceuticals, Inc., et al. v. Warner Chilcott Public Limited Co., et al.

Faruqi & Faruqi LLP is pleased to announce the Court’s preliminary approval of a settlement in Mylan Pharmaceuticals, Inc., et al. v. Warner Chilcott Public Limited Co., et al., Civ. No. 12-3824 (E.D.Pa.) (the “Settlement”). This case involves claims that Defendants violated the antitrust laws relating to the sale of prescription pharmaceutical Doryx® to direct purchasers such as wholesalers. The Settlement provides for $15,000,000 in cash to be paid to the direct purchaser class members, who are defined in the Settlement as entities that purchased Doryx® directly from  any of the Defendants at any time between July 18, 2008 and December 31, 2013.  A final approval hearing on the Settlement will be held on June 9, 2014 at 10:00 a.m. before U.S. District Court Judge Paul S. Diamond in Courtroom 6B at the United States District Court for the Eastern District of Pennsylvania, 601 Market Street, Philadelphia, PA 19106. Notice is being mailed to class members on March 4, 2014 and class members shall have until April 3, 2014 to object/opt-out of the Settlement. Information about the Settlement will be posted here on  www.faruqilaw.com. Below are the Class Notice, the Settlement Agreement,  the Court’s  February 18, 2014 Order preliminarily approving the Settlement, the Consolidated Amended Complaint filed on August 13, 2013 and Plaintiffs’ motion for preliminary approval of the Settlement and Plaintiffs’ motion for attorneys’ fees, reimbursement of expenses and incentive awards to the class representatives.